Anipryl® for Dogs: Treating Canine Cognitive Dysfunction & PDH

Anipryl for Dogs

Anipryl® for Dogs: Treating Canine Cognitive Dysfunction & PDH

Anipryl® (Selegiline Hydrochloride Tablets) Information

Indications
  • Control of clinical signs associated with canine Cognitive Dysfunction Syndrome (CDS)
  • Control of clinical signs associated with uncomplicated canine Pituitary Dependent Hyperadrenocorticism (PDH)
FormTablets
SpeciesCanine
Mechanism of Action
  • Selective monoamine oxidase-B (MAO-B) inhibitor
  • Enhances catecholamine neuron activity
  • Increases dopamine levels in dogs
Key Benefits
  • Targets both CDS and PDH signs
  • Does not require specific lab testing to begin treatment
  • Can be administered with food
  • Available in multiple dosage strengths
Dosing Instructions
  • CDS: 0.5–1.0 mg/kg orally once daily (preferably in the morning). Start with nearest whole tablet. Adjust based on response.
  • PDH: 1.0 mg/kg orally once daily. If no improvement after 2 months, increase to max 2.0 mg/kg. Re-evaluate after 1 month at higher dose if needed.
  • Monitor closely for adverse effects when increasing dosage.
Safety Information
  • Do not use with ephedrine, opioids, phenylpropanolamine, other MAO inhibitors (e.g., amitraz), or some antidepressants
  • Not recommended in dogs with known hypersensitivity to selegiline
  • Common side effects: vomiting, diarrhea, behavioral changes (e.g., hyperactivity, restlessness)
Anipryl® for Dogs: Treating Canine Cognitive Dysfunction & PDH

Discover how Anipryl® (selegiline hydrochloride) aids in managing canine cognitive dysfunction and pituitary-dependent hyperadrenocorticism in dogs.

THE RAJASTHAN EXPRESS